While the tau protein was originally characterized as a late-stage component of AD pathology, the identification of mutations within the MAPT gene itself in patients with clinical dementia and a parkinsonian phenotype (i.e. FTDP-17) [3] demonstrated that tau, in and of itself, is capable of causing neurodegenerative disease. This evidence concerns the gene MAPT and dementia.